Filing Details
- Accession Number:
- 0001610717-23-000289
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-09-19 19:52:07
- Reporting Period:
- 2023-09-19
- Accepted Time:
- 2023-09-19 19:52:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1885522 | Neumora Therapeutics Inc. | NMRA | Biological Products, (No Disgnostic Substances) (2836) | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 318154 | Amgen Inc | One Amgen Center Drive Thousand Oaks CA 91320 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-09-19 | 33,603,948 | $0.00 | 33,603,948 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2023-09-19 | 1,764,705 | $17.00 | 35,368,653 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A-2 Preferred Stock | Disposition | 2023-09-19 | 32,754,291 | $0.00 | 32,754,291 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2023-09-19 | 849,657 | $0.00 | 849,657 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.
Billionaire Hedge Funds
